Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20626748 | 0.93 | MAPT (0.46) | MAPTALDH1A1HTTHPGDMAPK1 | |
| SCHEMBL19902239 | 0.78 | ALDH1A1 (0.43) | MAPTALDH1A1HTTHPGDMAPK1 | |
| SCHEMBL31755975 | 0.62 | SMN1; SMN2 (0.61) | MAPTALDH1A1HTTHPGDMAPK1 | |
| SCHEMBL17476716 | 0.61 | MAPT (0.38) | MAPTALDH1A1HTTHPGDMAPK1 | |
| SCHEMBL4134576 | 0.56 | HTT (0.53) | MAPTALDH1A1HTTMAPK1LMNA | |
| SCHEMBL13177328 | 0.55 | APAF1 (0.50) | MAPTALDH1A1HTTHPGDMAPK1 | |
| SCHEMBL29951525 | 0.54 | APAF1 (0.49) | MAPTALDH1A1HTTHPGDMAPK1 | |
| SCHEMBL30078644 | 0.53 | NPSR1 (0.39) | ALDH1A1HTTMAPK1LMNA | |
| SCHEMBL31488029 | 0.52 | ALDH1A1 (0.37) | MAPTALDH1A1HTTHPGDMAPK1 | |
| SCHEMBL28621813 | 0.52 | HTT (0.33) | ALDH1A1HTTMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174064-B2 | Photoactive energetic materials | TRIAD NATIONAL SECURITY, LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-9902748-B2 | Photoactive energetic materials | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902748-B2 | Photoactive energetic materials | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160031767-A1 | PHOTOACTIVE ENERGETIC MATERIALS | TRIAD NATIONAL SECURITY, LLC | 2016-02-04 | — | — | US | disclosed |
| US-20160031767-A1 | PHOTOACTIVE ENERGETIC MATERIALS | TRIAD NATIONAL SECURITY, LLC | 2016-02-04 | — | — | US | disclosed |
| US-6342589-B1 | REACTING 3,6-BIS(3,5-DIMETHYLPYRAZOL-1-YL)-1,2,4,5-TETRAZINE WITH HYDRAZINE; FURTHER REACTING WITH N-BROMOSUCCINIMIDE IN ACETONITRILE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY | 2002-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174064-B2 | Photoactive energetic materials | NOX5, TRPM5, MT-ND5 | MAPT 1579/4885ALDH1A1 706/4885HTT 1534/4885 |
| US-20160031767-A1 | PHOTOACTIVE ENERGETIC MATERIALS | NOX5, TRPM5, MT-ND5 | MAPT 1579/4885ALDH1A1 706/4885HTT 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.